 Nature.com | Success of immunomodulators in MS shifts discovery focus to neuroprotection Nature.com The other Phase III candidates include Sanofi's oral dihydroorotate dehydrogenase inhibitor teriflunomide, Roche/Biogen Idec's injectable CD20-specific mAb ocrelizumab and Biogen Idec's injectable interleukin-2-specific mAb daclizumab. ... |
